论文部分内容阅读
血管靶向抗肿瘤药物的出现,标志着肿瘤治疗进入新的纪元。但是由于血管靶向抗肿瘤药物选择性作用于肿瘤血管,也带来了临床试验中重要的临床安全问题—其潜在的心血管不良反应。通过对血管靶向抗肿瘤药物可能产生的心血管不良反应及发生机制的分析,提出如何正确应对血管靶向肿瘤药物临床试验中心血管毒性作用的预防及治疗。
The emergence of vascular targeted anti-tumor drugs, marking the new era of cancer treatment. However, due to the selective targeting of vascular targeted antitumor drugs to tumor blood vessels, it also poses an important clinical safety issue in clinical trials - its potential cardiovascular adverse effects. Through the analysis of cardiovascular adverse reactions and mechanisms that vascular targeting anticancer drugs may produce, this paper proposes how to correctly deal with the prevention and treatment of vascular toxicity in the clinical trials of vascular targeted oncology drugs.